Target intelligence / Profile preview

Sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A)

Target
SMPDL3A
Molecular classification
Enzyme, Metallophosphodiesterase family, Acid sphingomyelinase homolog
01

Overview

Sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) is a secreted, N-linked glycoprotein enzyme of the metallophosphodiesterase family, closely related to human acid sphingomyelinase (aSMase) but lacking sphingomyelinase activity. Instead, SMPDL3A displays strong nucleotide phosphodiesterase activity, hydrolyzing nucleotide di- and triphosphates—including modified nucleotides such as CDP-choline, CDP-ethanolamine, and ADP-ribose—at acidic and neutral pH. The enzyme is upregulated in human macrophages by cholesterol loading, liver X receptor ligands, and cyclic AMP, potentially reducing extracellular levels of pro-inflammatory nucleotides and supporting anti-inflammatory signaling in atherosclerotic lesions. Structural studies reveal a binuclear Zn(2+)-dependent catalytic site similar to other acid sphingomyelinase family members, but with unique substrate preferences. SMPDL3A is also upregulated in certain human tumors and may serve as a functional link between lipid metabolism, nucleotide signaling, and inflammation.

Other names
Cyclic GMP-AMP phosphodiesterase SMPDL3AASML3A2',3'-cGAMP phosphodiesterase SMPDL3AASM-like phosphodiesterase 3aFLJ20177ASM3AyR36GH4.1Acid sphingomyelinase-like phosphodiesterase 3a0610010C24Rik
02

Mechanism of action

Catalyzes the hydrolysis of nucleotide di- and triphosphates, such as cytidine 5'-diphosphocholine (CDP-choline), cytidine diphosphate ethanolamine, and ADP-ribose, but not sphingomyelin

03

Biological functions

Nucleotide phosphodiesterase activityNegative regulation of cGAS/STING signaling pathwayParticipates in nucleoside triphosphate catabolic processesModulation of pro-inflammatory nucleotide levelsPutative anti-inflammatory effects in macrophages, particularly in atherosclerotic lesions
04

Disease associations

AtherosclerosisInflammatory disordersCancer (noted as upregulated in bladder tumor versus normal urothelium)
05

Safety considerations

No specific therapeutic safety concerns documented; potential off-target metabolic effects should be considered due to its regulation of extracellular nucleotides
06

Biomarkers

Potential biomarker for macrophage activation in atherosclerosisIncreased levels may indicate anti-inflammatory macrophage response in cholesterol-rich environments

Beyond the preview

Go deeper on Sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call